menu search

VPHIF / Valeo Pharma secures public reimbursement for Redesca and Redesca HP in British Columbia

Valeo Pharma secures public reimbursement for Redesca and Redesca HP in British Columbia
Valeo Pharma Inc said it has successfully entered into a Product Listing Agreement (PLA) with the British Columbia Minister of Health for the listing and public reimbursement of Redesca and Redesca HP, its low molecular weight heparin (LMWH) biosimilar for the prevention and treatment of thromboembolic disorders. As a result, both drugs have been added to the British Columbia PharmaCare list of medications. Read More
Posted: Mar 22 2022, 09:15
Author Name: Proactive Investors
Views: 111493

VPHIF News  

Valeo Pharma CEO credits Enerzair for strong position on Canada's top-growing companies list

By Proactive Investors
October 5, 2023

Valeo Pharma CEO credits Enerzair for strong position on Canada's top-growing companies list

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) CEO Steve Saviuk joined Proactive's Stephen Gunnion to discuss the company's strong position on the Globe an more_horizontal

Valeo Pharma secures spot on Canada's top-growing companies list

By Proactive Investors
October 4, 2023

Valeo Pharma secures spot on Canada's top-growing companies list

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) highlighted to investors that it has placed at spot 151 on the Globe and Mail's Report on Business annual lis more_horizontal

Valeo Pharma reports record quarterly revenue or strong demand for Enerzair and Atectura therapies

By Proactive Investors
September 14, 2023

Valeo Pharma reports record quarterly revenue or strong demand for Enerzair and Atectura therapies

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported its seventh consecutive rise in revenues to a quarterly record due to strong growth in its Enerz more_horizontal

Valeo Pharma raises funds totalling $4.5M

By Proactive Investors
September 1, 2023

Valeo Pharma raises funds totalling $4.5M

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has closed a non-brokered private placement offering, raising gross proceeds of $3.92 million. The company a more_horizontal

Valeo Pharma bolsters board with two new directors

By Proactive Investors
June 22, 2023

Valeo Pharma bolsters board with two new directors

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said Tamara Close and Didier Leconte have both joined its board of directors, noting that following the appo more_horizontal

Valeo Pharma reports record quarterly revenues

By Proactive Investors
June 14, 2023

Valeo Pharma reports record quarterly revenues

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported record quarterly revenues of $13.6 million for its second quarter ending April 30, 2023, repr more_horizontal

Valeo Pharma expects 2Q revenues to set quarterly record

By Proactive Investors
May 25, 2023

Valeo Pharma expects 2Q revenues to set quarterly record

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said it expects revenues in the second quarter to exceed $13.5 million, a quarterly record, with operating ex more_horizontal

Valeo Pharma reports record 1Q revenue and gross profit buoyed by new products and higher market share

By Proactive Investors
March 16, 2023

Valeo Pharma reports record 1Q revenue and gross profit buoyed by new products and higher market share

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said its revenue for the first quarter ended January 31, 2023, rose by 210% to a record $13.2 million, up fro more_horizontal


Search within

Pages Search Results: